Wave Life Sciences Ltd. (WVE)

Market Cap	1.32B -11.0%
Revenue (ttm)	42.73M -60.5%
Net Income	-204.38M
EPS	-1.21
Shares Out	188.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,058,047
Open	6.98
Previous Close	7.09
Day's Range	6.83 - 7.10
52-Week Range	5.02 - 21.73
Beta	-1.32
Analysts	Strong Buy
Price Target	30.25 (+330.91%)
Earnings Date	May 7, 2026

About WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 317
• Stock Exchange: NASDAQ
• Ticker Symbol: WVE
• Website: https://wavelifesciences.com

Financial Performance

In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.

Analyst Summary

According to 16 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $30.25, which is an increase of 330.91% from the latest price.

Price Target

$30.25

(330.91% upside)

Analyst Consensus: Strong Buy